Monobenzone depigmentation: what drives patient satisfaction in vitiligo

A retrospective cohort study published in the Journal of the American Academy of Dermatology, Volume 95, Issue 5, November 2026, has examined which factors correlate with patient satisfaction after monobenzone depigmentation therapy for vitiligo. Authors JennaKay Colquitt, Stella X. Chen, Olayemi Sokumbi, Richard J. Butterfield, and Yul W. Yang analyzed the records to identify variables that track with how patients rate their outcome following treatment with monobenzone, the topical depigmenting agent used in extensive vitiligo when repigmentation is no longer a realistic goal.

The study appeared in the November 2026 issue of JAAD, one of the field's highest-impact journals. Retrospective cohort designs like this one can't prove causation, but they can flag which patient and treatment characteristics deserve prospective validation — and that's the practical value here.

Why monobenzone, and why satisfaction matters

Monobenzone (monobenzyl ether of hydroquinone) is reserved for patients with widespread, refractory vitiligo — typically those for whom medical and surgical repigmentation strategies have failed or are unlikely to work. The goal shifts from restoring pigment to removing it completely, creating a uniform skin tone instead of a patchwork of depigmented and pigmented areas.

That trade-off makes patient satisfaction an unusually important endpoint. A therapy that cosmetically evens the skin but leaves the patient dissatisfied with the process, timeline, or final result isn't a success by most patient-reported standards. Yet satisfaction data for monobenzone remain sparse relative to the drug's long history of use.

What does this change for practice?

For clinicians counseling vitiligo patients on depigmentation, the study offers correlational evidence on which factors align with higher satisfaction. That's the practical question dermatologists ask before recommending an irreversible, months-long course of topical depigmentation — and the cohort gives them something more concrete than anecdote to anchor the conversation.

The authors — Colquitt, Chen, Sokumbi, Butterfield, and Yang — conducted the work as a retrospective review, meaning outcomes were drawn from existing clinical records rather than a prospective trial protocol. Details of cohort size, satisfaction measurement instrument, and follow-up duration appear in the full article in JAAD Volume 95, Issue 5.

The caveats, stated plainly

Correlation isn't causation. A retrospective design carries inherent selection bias: patients who complete therapy and return for follow-up are the ones whose data populate the chart review. Confounders — vitiligo extent, skin phototype, treatment duration, adherence — can all influence satisfaction independently of the factors the study isolates.

Even with those limits, the study fills a real gap. Vitiligo affects roughly 1% of the population worldwide, and for the subset with extensive, treatment-resistant disease, depigmentation is often the only cosmetic option left. Knowing who ends up satisfied — and who doesn't — helps set expectations before the first prescription.

What comes next

The natural follow-up is prospective validation: confirming the identified satisfaction correlates in a forward-looking cohort with standardized satisfaction instruments, ideally patient-reported outcome measures captured at fixed intervals. Until then, the November 2026 JAAD findings give dermatologists an evidence-based starting point for shared decision-making in monobenzone depigmentation — and a reminder that in irreversible therapy, satisfaction isn't a soft endpoint, it's the endpoint.